Thanatophoric dysplasia: a rare entity

Authors

  • Sangeeta Arya Department of Obstetrics and Gynecology, G.S.V.M. Medical College, Kanpur, UP, India
  • Kiran Pandey Department of Obstetrics and Gynecology, G.S.V.M. Medical College, Kanpur, UP, India
  • Disha Gupta Department of Obstetrics and Gynecology, G.S.V.M. Medical College, Kanpur, UP, India
  • Shefali Pande Department of Obstetrics and Gynecology, G.S.V.M. Medical College, Kanpur, UP, India

Keywords:

Thanatophoric dysplasia, Skeletal dysplasia, Pregnancy

Abstract

Thanatophoric dysplasia (TD), a rare and lethal skeletal dysplasia of neonatal period. Two clinical forms of Thanatophoric dysplasia have been described. TD is caused by specific autosomal dominant mutations in the gene that codifies for the Fibroblast Growth Factor Receptor 3 (FGFR3). The mutations constitutively activate the tyrosine kinase activity of the receptor. The estimated birth incidence is approximately 1/20,000 to 1/50,000. TD I being more frequent than TD II. Most individuals with TD die within the first few hours or days of life. Currently, specific therapeutic regiments do not exist. Prenatal diagnosis is available, both by ultrasonography and by molecular studies. This case report describes fetus with one of this rare disorder.

References

Lam AC, Lam YY, Tong TM et al. Thanatophoric dysplasia type 1 (TD 1) without “telephone receivers”. HK J Paediatr. 2006;11:320-3.

Bajaj P, Mangwana S, Logani KB, Kumari S, Gupta AK. Thanatophoric dwarfism. Indian Pediatr. 1993;30:802-5.

Cohen MM Jr. Achondroplasia, hypochondroplasia and thanatophoric dysplasia: clinically related skeletal dysplasias that are also related at the molecular level. Int J Oral Maxillofac Surg. 1998;27(6):451-5.

Langer LO Jr, Yang SS, Hall JG, Sommer A, Kottamasu SR, Golabi M et al. Thanatophoric dysplasia and cloverleaf skull. Am J Med Genet Suppl. 1987;3:167-79.

Rousseau A., Saugier P., Le Merrer M., Munnich A., Delezoide A. L., Maroteaux P., Bonaventure J., Narcy F., Sanak M. Stop codon FGFR3 mutations in thanatophoryc dwarfism type 1. Nat Genet. 1995;10:11-2.

Gorlin R. J. Fibroblast growth factors, their receptors and receptor disorders. J Craniomaxillofac Surg. 1997;25:69-79.

Sawai H., Komori S., Ida A., Henmi T., Bessho T., Koyama K. Prenatal diagnosis of thanatophoric dysplasia by mutational analysis of the fibroblast growth factor receptor 3 gene and a proposed correction of previously published PCR results. Prenat Diagn. 1999;19:21-4.

Gorlin R. J., Cohen M. M., Hennekam R. C. M. Syndromes of the Head and Neck. In: Gorlin R. J., Cohen M. M., Hennekam R. C. M., eds. The Chondrodysplasias. 4th ed. New York: Oxford University Press; 2001: 481.

Lee S. H., Cho J. Y., Song M. J., Min Y. J., Ban B. H., Lee Y. H., Cho B. J., Kim S. H. Fetal musculoskeletal malformations with a poor outcome: ultrasonographic, pathologic and radiographic findings. Korean J Radiol. 2002; 3:113-24.

MacDonald IM, Hunger AGW, MacLeod PM, MacMurray SB. Growth and development in thanatophoric dysplasia. Am J Med Genet. 1989;33:508-12.

Downloads

Published

2016-12-24